Wordt geladen...
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive breast cancer. However, about 70% of all treated patients will experience relapse or disease progression. This may be related to an insufficient targeting of the CD44(high)CD24...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3973200/ https://ncbi.nlm.nih.gov/pubmed/24675467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2014.115 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|